In recent years, genetic susceptibility has emerged as a crucial component in the development and progression of MASLD as polymorphisms (SNP—single nucleotide polymorphism) in the patatin-like phospholipase domain containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), glucokinase regulator (GCKR), membrane bound O-acyltransferase domain containing 7 (MBOAT7), hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), and mitochondrial amidoxime-reducing component 1 (MTARC1) genes, which regulate lipid metabolism and liver inflammation [9]. Here, MBOAT7 is linked to metabolic dysfunction-associated steatotic liver disease.